Handa Therapeutics LLC.: Handa Therapeutics Acquires FDA Approved Chronic Myeloid Leukemia Drug, PHYRAGO Tablets
PHYRAGO Represents the First and Only Improved Version of SPRYCEL® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / Handa Pharmaceu ...
PharmiWeb13h
Handa Therapeutics Acquires FDA Approved Chronic Myeloid Leukemia Drug, PHYRAGO (dasatinib) Tablets
PHYRAGO™ Represents the First and Only Improved Version of SPRYCEL® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / Handa ...
Medscape1d
Gaviscon® vs. Omeprazole in Symptomatic Treatment of Moderate Gastroesophageal Reflux
Background Medical management of GERD mainly uses proton pump inhibitors. Alginates also have proven efficacy. The aim of this trial was to compare short-term efficacy of an alginate (Gaviscon ...
Medscape1d
Room-temperature Storage of Medications Labeled for Refrigeration
This table may help to avoid unnecessary drug loss and expenditures due to improper storage temperatures. Although a full discussion of methods of stability information is beyond the scope of this ...